218 related articles for article (PubMed ID: 7997372)
1. [Treatment of dyskinetic syndromes].
Werdelin LM; Pakkenberg H
Nord Med; 1994; 109(12):341-4. PubMed ID: 7997372
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of dyskinetic syndromes].
Werdelin LM; Pakkenberg H
Ugeskr Laeger; 1994 Aug; 156(34):4801-4. PubMed ID: 7992412
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutical approach to involuntary movements (author's transl)].
Allain H; Sabouraud O
Sem Hop; 1979 Feb 8-15; 55(5-6):262-4. PubMed ID: 219537
[TBL] [Abstract][Full Text] [Related]
4. Involuntary movement disorders.
Still CN
Neurol Clin; 1984 Feb; 2(1):71-89. PubMed ID: 6239089
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hyperkinetic movement disorders.
Bressman SB; Greene PE
Neurol Clin; 1990 Feb; 8(1):51-75. PubMed ID: 2181268
[TBL] [Abstract][Full Text] [Related]
6. Movement disorders in the elderly.
Gilmore R
Geriatrics; 1984 Jun; 39(6):65-8, 72-6. PubMed ID: 6144615
[No Abstract] [Full Text] [Related]
7. [How to clinically approach involuntary movements].
Shibasaki H
Rinsho Shinkeigaku; 2003 Nov; 43(11):752-5. PubMed ID: 15152456
[TBL] [Abstract][Full Text] [Related]
8. Myoclonus and movement disorders.
Vercueil L
Neurophysiol Clin; 2006; 36(5-6):327-31. PubMed ID: 17336777
[TBL] [Abstract][Full Text] [Related]
9. Volitional control of involuntary movements.
Koller WC; Biary NM
Mov Disord; 1989; 4(2):153-6. PubMed ID: 2733707
[TBL] [Abstract][Full Text] [Related]
10. Therapeutics of disordered movement.
Sears ES
Am Fam Physician; 1977 Sep; 16(3):145-54. PubMed ID: 143204
[TBL] [Abstract][Full Text] [Related]
11. Drug treatment of diseases characterized by abnormal movements.
Marsden CD
Proc R Soc Med; 1973 Sep; 66(9):871-3. PubMed ID: 4281483
[No Abstract] [Full Text] [Related]
12. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
Chen JJ; Ondo WG; Dashtipour K; Swope DM
Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
[TBL] [Abstract][Full Text] [Related]
13. Treatment of dyskinetic and dystonic disorders with CF 25-397: clinical and pharmacological aspects.
Frattola L; Albizzati MG; Bassi S; Spano PF; Trabucchi M
Adv Biochem Psychopharmacol; 1980; 23():381-6. PubMed ID: 6446848
[No Abstract] [Full Text] [Related]
14. Case studies in movement disorders.
Evidente VG; Caviness JN; Adler CH
Semin Neurol; 2003 Sep; 23(3):277-84. PubMed ID: 14722823
[TBL] [Abstract][Full Text] [Related]
15. Pearls: hyperkinetic movement disorders.
Reich SG
Semin Neurol; 2010 Feb; 30(1):15-22. PubMed ID: 20127576
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin in movement disorders.
Papapetropoulos S; Singer C
Semin Neurol; 2007 Apr; 27(2):183-94. PubMed ID: 17390263
[TBL] [Abstract][Full Text] [Related]
17. [Movement disorders].
Azulay JP
Rev Prat; 2005 Jun; 55(11):1235-9. PubMed ID: 16164072
[No Abstract] [Full Text] [Related]
18. Respiratory problems in neurologic movement disorders.
Mehanna R; Jankovic J
Parkinsonism Relat Disord; 2010 Dec; 16(10):628-38. PubMed ID: 20674459
[TBL] [Abstract][Full Text] [Related]
19. [Trazodone in involuntary pathologic movements].
Rubino R; Provera P; Gilardengo P; Penza MT
Riv Neurol; 1984; 54(1):52-73. PubMed ID: 6718959
[TBL] [Abstract][Full Text] [Related]
20. Tetrabenazine in the treatment of hyperkinetic movement disorders.
Kenney C; Jankovic J
Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
